よむ、つかう、まなぶ。
資料4-2 フルオロウラシル (21 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00024.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第52回 8／31）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Junction Cancers. J Clin Oncol 2016; 34: 2736-42.
9) Blum Murphy MA, et al. A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX)
chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of
the stomach and gastroesophageal Junction. Am J Clin Oncol 2018; 41: 321-5.
10) Smyth EC, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol 2016; 27: v38-49.
11) Catalano V, et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic
gastric cancer in elderly patients with associated diseases. Gastric Cancer 2013; 16: 411-9.
12) Alberta Health services clinical practice guidelineGI-008 Version 6
13) Iqbal S, et al. Randomized, phase II study prospectively evaluating treatment of metastatic
esophageal, gastric, or gastroesophageal cancer by gene expression of ERCC1: SWOG S1201.
J Clin Oncol 2020; 38: 472-9.
14) Shah MA, et al.Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The
METGastric Randomized Clinical Trial. JAMA Oncol 2017; 3: 620-7.
15) Yoon HH, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced
esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind,
multicenter Phase II trial. Ann Oncol 2016; 27: 2196-203.
16) Bang YJ, et al. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor
ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction
cancer. Eur J Cancer 2019; 108: 17-24.
17) Malka D, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line
treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer 2019;
115: 97-106.
18) Cleary JM, et al. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric
adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer 2019; 125:
2213-21.
19) Mitani S, et al. A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory
to Standard Therapies. Adv Ther 2020; 37: 2853-64.
20) 船坂知華子, 他 進行再発胃癌に対する Modified FOLFOX6 療法の有用性に関する検討.
癌と化学療法 2020; 47: 49-53.
21) Kondoh C, et al. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum,
taxanes, and irinotecan. Gastric Cancer 2018; 21: 1050-7.
22) Tsuji K, et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer
refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn J Clin
21
9) Blum Murphy MA, et al. A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX)
chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of
the stomach and gastroesophageal Junction. Am J Clin Oncol 2018; 41: 321-5.
10) Smyth EC, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol 2016; 27: v38-49.
11) Catalano V, et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic
gastric cancer in elderly patients with associated diseases. Gastric Cancer 2013; 16: 411-9.
12) Alberta Health services clinical practice guidelineGI-008 Version 6
13) Iqbal S, et al. Randomized, phase II study prospectively evaluating treatment of metastatic
esophageal, gastric, or gastroesophageal cancer by gene expression of ERCC1: SWOG S1201.
J Clin Oncol 2020; 38: 472-9.
14) Shah MA, et al.Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without
Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The
METGastric Randomized Clinical Trial. JAMA Oncol 2017; 3: 620-7.
15) Yoon HH, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced
esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind,
multicenter Phase II trial. Ann Oncol 2016; 27: 2196-203.
16) Bang YJ, et al. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor
ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction
cancer. Eur J Cancer 2019; 108: 17-24.
17) Malka D, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line
treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. Eur J Cancer 2019;
115: 97-106.
18) Cleary JM, et al. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric
adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer 2019; 125:
2213-21.
19) Mitani S, et al. A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory
to Standard Therapies. Adv Ther 2020; 37: 2853-64.
20) 船坂知華子, 他 進行再発胃癌に対する Modified FOLFOX6 療法の有用性に関する検討.
癌と化学療法 2020; 47: 49-53.
21) Kondoh C, et al. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum,
taxanes, and irinotecan. Gastric Cancer 2018; 21: 1050-7.
22) Tsuji K, et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer
refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn J Clin
21